Innovation Pharmaceuticals Inc (IPIX)

[PlentyParanoid]

This we do know about prurisol as of now.
While waiting prurisol P2b results I got illustrative, again. I took a look at some dose ranging and other trials for Otezla and Xeljanz. Results for that peek are below. Correlations (R-squared values) with trend lines are so nice that it looks borderline educational. Then I plucked in what we currently know about prurisol. Draw your own conclusions. This time I stick to illustrating data, also known as facts.



Don’t get excited about what I call normalization. It is just a trick making it possible to display all values on the same chart. The base values for normalization are the smallest doses for which I could find some clinical data.

Also, don’t get excited about Xeljanz dose 15 mg/day (normalized value 7.5) docs will not give that to you. The approved dose cap is 10 mg/day. After that things got too risky for FDA. The same goes for Otezla beyond 60 mg/day dose (normalized value 6).

Obviously there have not been 3 separate trials with prurisol 200 mg/day dose. Those 3 green marker rings at prurisol normalized dose = 4 are PGA/IGA = 0/1 response percentage for 200 mg dose by PGA/IGA = 3 subjects in prurisol P2a trial converted to a corresponding PASI 75 response range. Where did I get the conversion values? They are from 14 clinical trial arms for Otezla and Xeljanz totaling 3130 subjects. I did the conversion by multiplying prurisol PGA/IGA = 0/1 response percentage with mean + standard deviation (high value), mean and mean – standard deviation (low value) for the PASI 75 to PGA/IGA = 0/1 ratios in those trials. BTW, the values are: mean = 1.06, stddev = 0.19, range: [0.90, 1.52].

Greyish placebo response range [5 %, 12 %] is also from the trials for Otezla and Xeljanz.